FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097506568> ?p ?o ?g. }

• W3097506568 endingPage "1757" @default.
• W3097506568 startingPage "1746" @default.
• W3097506568 abstract "Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by Food and Drug Administration (FDA) for HCC patients. We evaluated the therapeutic efficacy of cabozantinib, either alone or in combination, in vitro and in vivo.Human HCC cell lines and HCC mouse models were used to assess the therapeutic efficacy and targeted molecular pathways of cabozantinib, either alone or in combination with the pan-mTOR inhibitor MLN0128 or the checkpoint inhibitor anti-PD-L1 antibody.Cabozantinib treatment led to stable disease in c-Met/β-catenin and Akt/c-Met mouse HCC while possessing limited efficacy on Akt/Ras and c-Myc liver tumours. Importantly, cabozantinib effectively inhibited c-MET and ERK activity, leading to decreased PKM2 and increased p21 expression in HCC cells and in c-Met/β-catenin and Akt/c-Met HCC. However, cabozantinib was ineffective in inhibiting the Akt/mTOR cascade. Intriguingly, a strong inhibition of angiogenesis by cabozantinib occurred regardless of the oncogenic drivers. However, cabozantinib had limited impact on other tumour microenvironment parameters, including tumour infiltrating T cells, and did not induce programmed death-ligand 1 (PD-L1) expression. Combining cabozantinib with MLN0128 led to tumour regression in c-Met/β-catenin mice. In contrast, combined treatment with cabozantinib and the checkpoint inhibitor anti-PD-L1 antibody did not provide any additional therapeutic benefit in the four mouse HCC models tested.c-MET/ERK/p21/PKM2 cascade and VEGFR2-induced angiogenesis are the primary targets of cabozantinib in HCC treatment. Combination therapies with cabozantinib and mTOR inhibitors may be effective against human HCC." @default.
• W3097506568 created "2020-11-09" @default.
• W3097506568 creator A5014493738 @default.
• W3097506568 creator A5022582588 @default.
• W3097506568 creator A5031681400 @default.
• W3097506568 creator A5037736282 @default.
• W3097506568 creator A5040373155 @default.
• W3097506568 creator A5046126034 @default.
• W3097506568 creator A5047006975 @default.
• W3097506568 creator A5062134753 @default.
• W3097506568 creator A5065789169 @default.
• W3097506568 creator A5069612314 @default.
• W3097506568 creator A5070344581 @default.
• W3097506568 creator A5071390780 @default.
• W3097506568 creator A5083504533 @default.
• W3097506568 creator A5086326808 @default.
• W3097506568 creator A5091038323 @default.
• W3097506568 date "2020-11-03" @default.
• W3097506568 modified "2023-10-11" @default.
• W3097506568 title "Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma" @default.
• W3097506568 cites W1972389653 @default.
• W3097506568 cites W1998832402 @default.
• W3097506568 cites W2029324920 @default.
• W3097506568 cites W2046427955 @default.
• W3097506568 cites W2069436757 @default.
• W3097506568 cites W2087106096 @default.
• W3097506568 cites W2093538839 @default.
• W3097506568 cites W2094337993 @default.
• W3097506568 cites W2103562758 @default.
• W3097506568 cites W2152690616 @default.
• W3097506568 cites W2294090452 @default.
• W3097506568 cites W2411225414 @default.
• W3097506568 cites W2462145367 @default.
• W3097506568 cites W2560348108 @default.
• W3097506568 cites W2603421341 @default.
• W3097506568 cites W2737501041 @default.
• W3097506568 cites W2750691704 @default.
• W3097506568 cites W2776111084 @default.
• W3097506568 cites W2809889937 @default.
• W3097506568 cites W2883204623 @default.
• W3097506568 cites W2898267386 @default.
• W3097506568 cites W2914108153 @default.
• W3097506568 cites W2914763289 @default.
• W3097506568 cites W2965861340 @default.
• W3097506568 cites W3025022288 @default.
• W3097506568 cites W4232620598 @default.
• W3097506568 cites W4245403358 @default.
• W3097506568 doi "https://doi.org/10.1136/gutjnl-2020-320716" @default.
• W3097506568 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8089119" @default.
• W3097506568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33144318" @default.
• W3097506568 hasPublicationYear "2020" @default.
• W3097506568 type Work @default.
• W3097506568 sameAs 3097506568 @default.
• W3097506568 citedByCount "49" @default.
• W3097506568 countsByYear W30975065682021 @default.
• W3097506568 countsByYear W30975065682022 @default.
• W3097506568 countsByYear W30975065682023 @default.
• W3097506568 crossrefType "journal-article" @default.
• W3097506568 hasAuthorship W3097506568A5014493738 @default.
• W3097506568 hasAuthorship W3097506568A5022582588 @default.
• W3097506568 hasAuthorship W3097506568A5031681400 @default.
• W3097506568 hasAuthorship W3097506568A5037736282 @default.
• W3097506568 hasAuthorship W3097506568A5040373155 @default.
• W3097506568 hasAuthorship W3097506568A5046126034 @default.
• W3097506568 hasAuthorship W3097506568A5047006975 @default.
• W3097506568 hasAuthorship W3097506568A5062134753 @default.
• W3097506568 hasAuthorship W3097506568A5065789169 @default.
• W3097506568 hasAuthorship W3097506568A5069612314 @default.
• W3097506568 hasAuthorship W3097506568A5070344581 @default.
• W3097506568 hasAuthorship W3097506568A5071390780 @default.
• W3097506568 hasAuthorship W3097506568A5083504533 @default.
• W3097506568 hasAuthorship W3097506568A5086326808 @default.
• W3097506568 hasAuthorship W3097506568A5091038323 @default.
• W3097506568 hasBestOaLocation W30975065681 @default.
• W3097506568 hasConcept C121608353 @default.
• W3097506568 hasConcept C126322002 @default.
• W3097506568 hasConcept C190283241 @default.
• W3097506568 hasConcept C2776539811 @default.
• W3097506568 hasConcept C2778019345 @default.
• W3097506568 hasConcept C2778695046 @default.
• W3097506568 hasConcept C2781064419 @default.
• W3097506568 hasConcept C502942594 @default.
• W3097506568 hasConcept C55493867 @default.
• W3097506568 hasConcept C71924100 @default.
• W3097506568 hasConcept C75217442 @default.
• W3097506568 hasConcept C86803240 @default.
• W3097506568 hasConcept C98274493 @default.
• W3097506568 hasConceptScore W3097506568C121608353 @default.
• W3097506568 hasConceptScore W3097506568C126322002 @default.
• W3097506568 hasConceptScore W3097506568C190283241 @default.
• W3097506568 hasConceptScore W3097506568C2776539811 @default.
• W3097506568 hasConceptScore W3097506568C2778019345 @default.
• W3097506568 hasConceptScore W3097506568C2778695046 @default.
• W3097506568 hasConceptScore W3097506568C2781064419 @default.
• W3097506568 hasConceptScore W3097506568C502942594 @default.
• W3097506568 hasConceptScore W3097506568C55493867 @default.
• W3097506568 hasConceptScore W3097506568C71924100 @default.
• W3097506568 hasConceptScore W3097506568C75217442 @default.

• next